AU8874198A - Antisense treatment of pulmonary hypertension - Google Patents

Antisense treatment of pulmonary hypertension

Info

Publication number
AU8874198A
AU8874198A AU88741/98A AU8874198A AU8874198A AU 8874198 A AU8874198 A AU 8874198A AU 88741/98 A AU88741/98 A AU 88741/98A AU 8874198 A AU8874198 A AU 8874198A AU 8874198 A AU8874198 A AU 8874198A
Authority
AU
Australia
Prior art keywords
pulmonary hypertension
antisense treatment
antisense
treatment
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU88741/98A
Inventor
Timothy Higenbottam
Keith Mccormack
Adrian Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Publication of AU8874198A publication Critical patent/AU8874198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU88741/98A 1997-09-02 1998-09-02 Antisense treatment of pulmonary hypertension Abandoned AU8874198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718487.3A GB9718487D0 (en) 1997-09-02 1997-09-02 Pulmonary hypertension
GB9718487 1997-09-02
PCT/GB1998/002584 WO1999011778A1 (en) 1997-09-02 1998-09-02 Antisense treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
AU8874198A true AU8874198A (en) 1999-03-22

Family

ID=10818333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU88741/98A Abandoned AU8874198A (en) 1997-09-02 1998-09-02 Antisense treatment of pulmonary hypertension

Country Status (6)

Country Link
EP (1) EP1009822A1 (en)
JP (1) JP2001515011A (en)
AU (1) AU8874198A (en)
CA (1) CA2302167A1 (en)
GB (1) GB9718487D0 (en)
WO (1) WO1999011778A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
AU4007899A (en) * 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
ATE377645T1 (en) * 1999-03-18 2007-11-15 Queen Mary & Westfield College INHIBITORS OF ENDOTHELIN-1 SYNTHESIS
AU2001289861A1 (en) * 2000-09-19 2002-04-02 Epidauros Biotechnologie Ag Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications
WO2016083624A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for inhibiting the expression of edn1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279014B (en) * 1993-06-02 1997-07-16 Niall Keaney Device for controlling delivery of respiratory drugs
GB9320978D0 (en) * 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
GB2320900B (en) * 1997-01-07 2000-08-30 Univ Sheffield Inhalers

Also Published As

Publication number Publication date
EP1009822A1 (en) 2000-06-21
GB9718487D0 (en) 1997-11-05
CA2302167A1 (en) 1999-03-11
WO1999011778B1 (en) 1999-04-15
WO1999011778A1 (en) 1999-03-11
JP2001515011A (en) 2001-09-18

Similar Documents

Publication Publication Date Title
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
PL339551A1 (en) Derivatives of rezorcin
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU9319798A (en) Reduction of hair growth
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU4442799A (en) Antisense modulation of elk-1 expression
AU2585197A (en) Antisense approach to gene inhibition
AU8874198A (en) Antisense treatment of pulmonary hypertension
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
AU6883398A (en) Methods of treating bone loss
PL334769A1 (en) Derivatives of 5-aroylnaphtene
AU1853397A (en) Treatment of pulmonary inflammation
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
AU2042097A (en) Treatment for pulmonary fibrosis
PL335675A1 (en) Anticonvulsive derivatives of isoquinolinbenzamide
AU5587599A (en) Antisense modulation of tradd expression
ZA985064B (en) Derivatives of pentaerythrits
AU8102498A (en) Preparation of diaryl-benzopyrans
AU3757200A (en) Treatment of pulmonary hypertension
AU6920898A (en) Antisense inhibition of human stat-6
AU4985200A (en) Methods of treating hypertension
AU2619199A (en) Treatment of waxes
EP1143998A4 (en) Treatment of hypertension

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase